van Voorst, Henk http://orcid.org/0000-0002-2647-3557
Hoving, Jan W.
Koopman, Miou S.
Daems, Jasper D.
Peerlings, Daan
Buskens, Erik
Lingsma, Hester F.
Beenen, Ludo F. M.
de Jong, Hugo W. A. M.
Berkhemer, Olvert A.
van Zwam, Wim H.
Roos, Yvo B. W. E. M.
van Walderveen, Marianne A. A.
van den Wijngaard, Ido
Dippel, Diederik W. J.
Yoo, Albert J.
Campbell, Bruce C. V.
Kunz, Wolfgang G.
Emmer, Bart J.
Majoie, Charles B. L. M.
van Nuland, Rick
van der Lugt, Aad
van Es, Adriaan
van Doormaal, Pieter-Jan
van den Berg, René
Beenen, Ludo F. M.
Roosendaal, Stefan D.
Postma, Alida Annechien
Yo, Lonneke S. F.
Krietemeijer, G. Menno
Nijeholt, Geert J. Lycklama à
Martens, Jasper M.
Hammer, Sebastiaan
Meijer, Anton
Bokkers, Reinoud P. H.
van der Hoorn, Anouk
Gerrits, Dick
van Oostenbrugge, Robert
Coutinho, Jonathan M.
Truijman, Martine
Staals, Julie
van der Worp, H. Bart
Boogaarts, J.
Jansen, Ben
Zinkstok, Sanne
Truijman, Martine
Staals, Julie
Koudstaal, Peter
Keizer, Koos
Manschot, Sanne
Boiten, Jelis
Kerkhoff, Henk
Chalos, Vicky
Versteeg, Adriaan
Wolff, Lennard
van der Sluijs, Matthijs
Tolhuisen, Manon L.
Cate, Hugo ten
de Maat, Moniek
Donse-Donkel, Samantha
van Beusekom, Heleen
Taha, Aladdin
Barakzie, Aarazo
van de Graaf, Rob
van der Steen, Wouter
Treurniet, Kilian M.
van den Berg, Sophie
LeCouffe, Natalie
Kappelhof, Manon
Reinink, Rik
Rinkel, Leon
Brouwer, Josje
Bruggeman, Agnetha
Goldhoorn, Robert-Jan
Hinsenveld, Wouter
Pirson, Anne
Olthuis, Susan
Venema, Simone Uniken
Teeselink, Sjan
Sondag, Lotte
Collette, Sabine
Sterrenberg, Martin
Ghannouti, Naziha el
van der Steen, Laurine
Verheesen, Sabrina
Vranken, Jeannique
van Ahee, Ayla
Bongenaar, Hester
Smallegange, Maylee
Tilet, Lida
de Meris, Joke
Simons, Michelle
Pellikaan, Wilma
van Wijngaarden, Wilma
Blauwendraat, Kitty
Drabbe, Yvonne
Sandiman-Lefeber, Michelle
Katthöfer, Anke
Ponjee, Eva
Eilander, Rieke
van Loon, Anja
Kraus, Karin
Kooij, Suze
Slotboom, Annemarie
van der Minne, Friedus
Santegoets, Esther
Heiligers, Leontien
Martens, Yvonne
Vos, Jan Albert
Jansen, Ivo G. H.
Mulder, Maxim J. H. L.
Compagne, Kars C. J.
den Hartog, Sanne J.
Roozenbeek, Bob
Schonewille, Wouter J.
Wermer, Marieke J. H.
Hofmeijer, Jeannette
Nijeholt, Geert J. Lycklama à
de Bruijn, Sebastiaan F.
van Dijk, Lukas C.
Lo, Rob H.
van Dijk, Ewoud J.
Boogaarts, Hieronymus D.
de Vries, J.
de Kort, Paul L. M.
van Tuijl, Julia
Peluso, Jo P.
Fransen, Puck
van den Berg, Jan S. P.
van Hasselt, Boudewijn A. A. M.
Aerden, Leo A. M.
Dallinga, René J.
Uyttenboogaart, Maarten
Eschgi, Omid
Schreuder, Tobien H. C. M. L.
Heijboer, Roel J. J.
Keizer, Koos
den Hertog, Heleen M.
Sturm, Emiel J. C.
Sprengers, Marieke E. S.
Jenniskens, Sjoerd F. M.
van der Kallen, Bas F. W.
Bot, Joost
Ghariq, Elyas
van Proosdij, Marc P.
Dinkelaar, Wouter
Appelman, Auke P. A.
Hammer, Bas
Pegge, Sjoert
Vinke, Saman
Flach, H. Zwenneke
Sprengers, Rita
Elfrink, Marjan
Vossers, Marjolein
de Meris, Joke
Vermeulen, Tamara
Geerlings, Annet
van Vemde, Gina
Simons, Tiny
Messchendorp, Gert
Nicolaij, Nynke
Bodde, Karin
Kleijn, Sandra
Lodico, Jasmijn
Droste, Hanneke
Wollaert, Maureen
Jeurrissen, D.
Bos, Erna
Sandiman, Michelle
Aaldering, Nicoline
Zweedijk, Berber
Vervoort, Jocova
Romviel, Sharon
Kanselaar, Karin
Barning, Denn
Venema, Esmee
Geuskens, Ralph R.
van Straaten, Tim
Ergezen, Saliha
Harmsma, Roger R. M.
Muijres, Daan
de Jong, Anouk
Boers, Anna M. M.
Groot, P. F. C.
Mens, Marieke A.
van Kranendonk, Katinka R.
Alves, Heitor
Weterings, Annick J.
Kirkels, Eleonora L. F.
Voogd, Eva J. H. F.
Schupp, Lieve M.
Groot, Adrien E. D.
Konduri, Praneeta R.
Prasetya, Haryadi
Arrarte-Terreros, Nerea
Ramos, Lucas A.
,
,
,
Funding for this research was provided by:
Leading the Change
Article History
Received: 16 March 2023
Revised: 22 June 2023
Accepted: 1 July 2023
First Online: 20 September 2023
Declarations
:
: The scientific guarantor for this study is Charles BLM Majoie.
: The authors of this manuscript declare relationships with the following companies: Codman, Stryker, AngioCare, Medtronic, Covidien, EV3, MEDAC, LAMePRO, Penumbra, Top Medical, Concentric, Nicolab, Medtronic, Cerenovus, Bracco Imaging, Servier, Genentech, Vesalio, Philips, Zoll Circulation, Insera Therapeutics.WHvZ reports personal fees from Codman and from Stryker. DWJD report grants from the Dutch Heart Foundation, AngioCare, Medtronic/Covidien/EV3, MEDAC/LAMEPRO, Penumbra, Top Medical/Concentric, Stryker, and Cerenovus; consultation fees from Stryker, Bracco Imaging, and Servier, received by the Erasmus University Medical Centre outside this project. CBLMM reports grants from TWIN, during the conduct of the study and grants from CVON/Dutch Heart Foundation, European Commission, Dutch Health Evaluation Program, and from Stryker outside this project (paid to institution) and is shareholder of Nicolab. AJY reports Research grants from Medtronic, Cerenovus, Penumbra, Stryker, and Genentech. Consultant for Penumbra, Cerenovus, Nicolab, Philips, Vesalio, Zoll Circulation, and NIH/NINDS. YR is a shareholder of Nicolab. Equity interests in Insera Therapeutics and Nicolab. All other contributors report no conflicts of interest.
: One of the authors has significant statistical expertise: Erik Buskens, University Medical Center Groningen, Department of Epidemiology, coauthor of this manuscript.
: Written informed consent was waived by the Institutional Review Board.
: Patient inclusion was in adherence with the Declaration of Helsinki and was subject to an ethical board review. The CLEOPATRA study protocol has been reviewed by the Amsterdam UMC ethical review board and was waived for informed consent (internal reference: W19_281#19.334). Retrospective, large-scale, observational studies do not fall under the Medical Research Involving Human Subjects Act (WMO). For patients included in the MR CLEAN-NO IV (ISRCTN80619088, registered 31 October 2017), and MR CLEAN MED (ISRCTN76741621, registered 7 December 2017) trials, informed consent has been received previously. The ethical review board of the Erasmus MC has waived the requirement for informed consent for patients included in the MR CLEAN Registry (internal reference Erasmus MC: MEC-2014–235, 27 August 2014).
: Of all 701 patients considered in this study, data from 622 have previously been reported. Patients were included in the MR CLEAN NO IV trial (<i>n</i> = 227), MR CLEAN MED trial (<i>n</i> = 117), and MR CLEAN Registry (<i>n</i> = 278). All included patients were selected as a subset of the overall MR CLEAN NO IV, MR CLEAN MED, and MR CLEAN Registry populations. We used patients included in these studies to extract population statistics (age, sex) and functional outcomes that, combined with literature, were used to simulate long-term functional outcome, costs, and QALYs. Based on simulations we describe the effect on costs and QALYs of various scenarios for screening patients with CTP. Current other studies did not have related research aims or hypotheses. We selected these patients based on the presence of CTP before EVT to describe a realistic cohort of patients that receive CTP. Patients included in the MR CLEAN NO IV (<i>n</i> = 227) and MR CLEAN MED (<i>n</i> = 117) have been studied in a randomized controlled trial setting for the effect of intravenous alteplase (0.9 mg/kg) before EVT and the effect of heparin and aspirin before endovascular treatment respectively. Functional outcome and population characteristics of the patients included MR CLEAN Registry (<i>n</i> = 278) have been reported before. A similar cost-effectiveness analysis for CTP based on the same population is under review. However, this other study considers CTP for EVT patient selection and not for EVT eligible occlusion detection.There exists a pre-print, .
: